海通证券股份有限公司关于沈阳兴齐眼药股份有限公司 2024 年半年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：兴齐眼药 | | --- | --- | | 保荐代表人姓名：石迪 | 联系电话：021-23187088 | | 保荐代表人姓名：王显 | 联系电话：021-23185968 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2、督导公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 | | | 但不限于防止关联方占用公司资源的制度、募 | 是 | | 集资金管理制度、内控制度、内部审计制度、 | | | 关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-044 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的SQ-22031滴眼液于 近日完成了"评估SQ-22031滴眼液在健康受试者中单次/多次给药的安全性、耐 受性和药代动力学的单中心、随机、双盲、安慰剂对照I期临床试验"首例受试 者入组，正式进入该临床试验。现将有关内容公告如下： 一、基本情况 药物名称：SQ-22031 滴眼液 注册分类：治疗用生物制品 1 类 剂型：滴眼剂 适应症：神经营养性角膜炎 临床试验批准通知书编号：2024LP01687、2024LP01688、2024LP01689、 2024LP01690 沈阳兴齐眼药股份有限公司 关于 SQ-22031 滴眼液Ⅰ期临床试验首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1 和药代动力学特征。 三、同类药品的情况 截至本公告披露日，经查询国家药品监督管理局网站，尚无同品种药品批准 上市。 四、对公司的影响 临床试验分期：Ⅰ期 申办方：沈阳兴齐眼药股份有限公司 二、临床试验相关情况 神经营养性角膜炎（Neu ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 122.50 CNY [4][2]. Core Insights - The company reported significant revenue growth, achieving 892 million CNY in revenue for the first half of 2024, a year-on-year increase of 30.10%, and a net profit of 169 million CNY, up 92.95% year-on-year [1]. - The eye drop segment saw accelerated revenue growth, particularly due to the launch of low-concentration atropine, which contributed to a 62.97% increase in revenue for this product line [1]. - The company has a rich product pipeline with 58 approved ophthalmic drugs, including 35 listed in the medical insurance directory, which supports its revenue base [1]. Financial Performance Summary - For the first half of 2024, the company achieved a gross profit margin of 80.3%, with net profit margins projected to reach 19.7% by 2024 [2][12]. - The forecasted net profits for 2024, 2025, and 2026 are 501 million CNY, 734 million CNY, and 970 million CNY respectively, indicating strong growth potential [2][12]. - The company's earnings per share (EPS) is projected to be 2.87 CNY for 2024, increasing to 5.56 CNY by 2026 [2][12].

证券代码：300573 证券简称：兴齐眼药 沈阳兴齐眼药股份有限公司 投资者关系活动记录表 编号：2024-004 | --- | --- | --- | --- | --- | --- | |---------------------------|-------|--------------------------------|-------------|------------------------------------------------|----------------------------------------------------------------| | | □ | 特定对象调研 □ | | 分析师会议 | | | 投资者关系 | □ | 媒体采访 □ | | 业绩说明会 | | | 活动类别 | □ | 新闻发布会 | □ | 路演活动 | | | | □ | 现场参观 √ | | 其他（电话会议） | | | 参与单位名称 及人员姓名 | | 详见附件：参加交流活动人员名单 | | | | | 时间 2024 | | 年 08 月 29 日 | 15:00-15:55 | ...

2024 年 08 月 29 日 兴齐眼药(300573.SZ) 具备大单品潜力 事件： 2024 年 8 月 28 日公司发布 2024 年半年度报告，2024H1 公司实现营 收 8.92 亿元，同比增长 30.10%；实现归母净利润 1.69 亿元，同比 增长 92.95%。 得益于核心产品的快速放量，2024H1 公司业绩实现快速增长： 收入端，2024H1 公司实现营收 8.92 亿元，同比增长 30.10%。其中， 凝胶剂/眼膏剂、滴眼剂、医疗服务分别实现营收 1.76 亿元（-0.58%）、 5.12 亿元（+62.97%）、1.64 亿元（+5.44%）。 利润端，2024H1 公司实现归母净利润 1.69 亿元，同比增长 92.95%。 得益于 0.01%硫酸阿托品滴眼液等核心产品的销售放量，公司业绩实 现快速增长。 0.01%硫酸阿托品滴眼液率先获批，销售有望持续放量： 公司的 0.01%硫酸阿托品滴眼液于 2024 年 3 月获批，主要用于延缓 儿童的近视进展，考虑到儿童近视患者群体基数较大，且公司持续积 极进行渠道推广，该品种具备大单品潜力且销售有望持续放量。此外， 公司积极开展 0. ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-042 沈阳兴齐眼药股份有限公司 关于 2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）、《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及 《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》的相关规 定，沈阳兴齐眼药股份有限公司（以下简称"公司"、"本公司"）就 2024 年半年 度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可[2021]1343 号文批准，公司向特定对 象发行人民币普通股5,763,282股，募集资金总额为人民币599,669,492.10元， 实际收到募集资金为人民币 581,870,425.73 元（已扣除承销费用（含增值税））。 上述募集资 ...

Financial Performance - The company's operating revenue for the current period is ¥891,799,280.33, representing a 30.10% increase compared to ¥685,470,748.67 in the same period last year[38]. - Net profit attributable to shareholders for the current period is ¥169,320,445.67, a significant increase of 92.95% from ¥87,754,641.26 in the previous year[38]. - The net profit after deducting non-recurring gains and losses is ¥168,612,418.22, reflecting a 96.55% increase compared to ¥85,785,478.10 last year[38]. - Cash generated from operating activities is ¥186,739,212.34, up 79.76% from ¥103,883,336.66 in the same period last year[38]. - Basic and diluted earnings per share are both ¥0.99, marking a 90.20% increase from ¥0.51 in the previous year[38]. - The company's total assets at the end of the current period are ¥2,082,705,443.09, a 2.91% increase from ¥2,023,844,736.22 at the end of the previous year[38]. - Net assets attributable to shareholders decreased by 11.00% to ¥1,504,080,488.86 from ¥1,689,920,857.47 at the end of the previous year[38]. - The company achieved a net profit attributable to ordinary shareholders of 169,320,445.67 CNY for the first half of 2024, with a cumulative distributable net profit of 409,936,982.97 CNY[108]. - The company reported a total revenue of 1,734.76 million RMB for the first half of 2024, reflecting a growth of 12.5% compared to the same period last year[158]. Research and Development - The company plans to increase R&D investment and expand its ophthalmic product line to mitigate risks from intensified industry competition and the emergence of alternative drugs[7]. - The company is committed to advancing key R&D projects and expanding its R&D pipeline to manage risks associated with unmet project expectations[9]. - The company is focused on developing new ophthalmic drugs and expanding its product line[29]. - The company’s R&D investment amounted to CNY 92.90 million, reflecting a 7.88% increase from CNY 86.11 million in the previous year, indicating a continued focus on innovation[71]. - The company is investing 200 million yuan in R&D for new technologies aimed at enhancing product efficacy and user experience[192]. - The company has established a comprehensive eye drug product system, focusing on professional and diversified development in the ophthalmic field[52]. Market Strategy and Expansion - The company aims to enhance its market share and sales coverage to address potential risks of slowing performance and unmet expectations due to intensified market competition[8]. - The company has formed stable partnerships with major pharmaceutical distributors and e-commerce platforms to enhance sales growth across various channels[60]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[121]. - Market expansion efforts include entering two new provinces, which are expected to contribute an additional 150 million yuan in revenue by year-end[192]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for this purpose[192]. Compliance and Risk Management - The company is focused on maintaining compliance and improving operational strategies to navigate the evolving regulatory landscape in the pharmaceutical industry[6]. - The company acknowledges the risks associated with rapid scale expansion and plans to enhance management training and recruit new personnel to address these challenges[13]. - The company recognizes the ongoing risks from industry policy adjustments and drug price fluctuations, and it is enhancing its response capabilities to these changes[5]. - The company is implementing measures to mitigate risks associated with rising costs and quality control challenges in the pharmaceutical industry[94]. - The company is facing risks related to industry policy adjustments and intensified competition, prompting a need for strategic responses[93]. Environmental Responsibility - The company has applied for a pollutant discharge permit valid from July 28, 2023, to July 27, 2028[118]. - The company reported a total wastewater discharge of 319 tons, with a COD concentration of 0.403 g/L[118]. - The company has completed the environmental impact assessment for the R&D center construction project in the first half of 2024[118]. - The company upgraded its wastewater treatment plant in 2023, increasing the daily processing capacity to 480m³/day[119]. - The company conducts manual monitoring of boiler emissions once a month to ensure compliance with environmental standards[120]. Shareholder Relations and Dividends - The company reported a cash dividend of 5 RMB per 10 shares (including tax) based on 174,424,871 shares, with no bonus shares issued[15]. - The company plans to distribute a cash dividend of 5.00 CNY per 10 shares (including tax), totaling 87,212,435.50 CNY, based on a total share capital of 174,424,871 shares[108]. - The total cash dividend distributed since the company's listing has reached 732 million CNY, with 11 cash dividend distributions implemented[100]. - The company maintains a profit distribution policy that emphasizes continuity and stability, ensuring that investors share in the company's development achievements[100]. - The company has established multiple channels for investor relations management, including a dedicated investor hotline and a WeChat public account[101]. Corporate Governance - The company held its first extraordinary general meeting on January 5, 2024, approving the election of the fifth board of directors and supervisory board members[149]. - The company’s board of directors and supervisory board elections were conducted in accordance with the relevant regulations[149]. - The company has not engaged in any major related party transactions during the reporting period[137]. - The semi-annual financial report has not been audited, indicating that the figures presented are preliminary[169].

第五届监事会第四次会议决议公告 证券代码：300573 证券简称：兴齐眼药 公告编号：2024-037 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司 一、监事会会议召开情况 1、本次监事会由监事会主席曲晓禹女士召集，会议通知于2024年8月16日通 过电子邮件的形式送达至全体监事，监事会会议通知中包括会议的相关资料，同 时列明了会议的召开时间、地点、内容和方式。 2、本次监事会于 2024 年 8 月 27 日在公司会议室以现场会议方式召开。 3、本次监事会应到3人，实际出席会议人数为3人。 表决结果：3 票赞成，0 票反对，0 票弃权。 （二）审议通过《关于<2024 年半年度利润分配预案>的议案》 监事会认为，公司 2024 年半年度利润分配预案是结合公司 2024 年半年度实 际经营情况和未来经营发展的需要做出的，不存在损害公司及其他股东，特别是 中小股东利益的情形，同意本次利润分配预案。 1 4、本次监事会由监事会主席曲晓禹女士主持。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的 ...

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于 2024 年 8 月 27 日召开 第五届董事会第四次会议及第五届监事会第四次会议，审议通过《关于<2024 年 半年度利润分配预案>的议案》，该利润分配预案尚需公司 2024 年第二次临时股 东大会审议通过后方可实施。现将有关事宜公告如下： 证券代码：300573 证券简称：兴齐眼药 公告编号：2024-040 沈阳兴齐眼药股份有限公司 关于 2024 年半年度利润分配预案的公告 一、利润分配预案 2024 年 半 年 度 公 司 实 现 归 属 于 上 市 公 司 普 通 股 股 东 的 净 利 润 为 169,320,445.67 元，母公司实现净利润 153,093,048.98 元；截至 2024 年 6 月 30 日公司合并报表累计可供投资者分配的净利润为 409,936,982.97 元，母公司 累计可供投资者分配的净利润为 238,140,233.67 元。 在符合公司利润分配政策并兼顾公司可持续发展原则的前提下，公司 2024 年半年度利润分配预案 ...

授权公司董事长及其授权人士代表公司全权办理该授信事宜，包括但不限于 代表公司签订以及根据公司情况修改相关文件、合同，由此产生的法律、经济责 任全部由公司承担。 本次申请银行授信额度无需提交公司股东大会审议。 关于向银行申请授信的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于 2024 年 8 月 27 日召开 第五届董事会第四次会议，审议通过了《关于向银行申请授信的议案》，现将相 关情况公告如下： 根据正常业务的资金需求，公司拟向中国光大银行沈阳和平支行申请 8,000 万元人民币授信额度，向中国工商银行沈阳经济技术开发区支行申请新增 8,000 万元人民币授信额度。上述两家银行的授信额度用于办理流动资金贷款、银行承 兑汇票、信用证、保函等信贷业务。 以上授信额度不等于公司的实际融资金额，实际融资金额应在授信额度内以 银行与公司实际发生的融资金额为准。 证券代码：300573 证券简称：兴齐眼药 公告编号：2024-041 沈阳兴齐眼药股份有限公司 特此公告。 沈阳兴齐眼药股份有限公司 董事会 2024 年 ...